Santhera Pharmaceuticals's successful turnaround is continuing apace with its treatment for Duchenne muscular dystrophy (DMD), vamorolone, filed with regulators on both sides of the Atlantic but the Swiss biotech is going to need more funds soon to get the drug to market.
The company and partner Reveragen BioPharma, Inc. have completed the rolling submission of a new drug application and are seeking a priority review for vamorolone from the US Food and Drug Administration to treat DMD